Strategic Wealth Partners Ltd. bought a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 40,683 shares of the company's stock, valued at approximately $1,874,000. Strategic Wealth Partners Ltd. owned 0.15% of Establishment Labs as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new stake in shares of Establishment Labs during the 4th quarter worth about $12,898,000. R Squared Ltd acquired a new position in Establishment Labs in the fourth quarter worth approximately $36,000. Handelsbanken Fonder AB raised its position in Establishment Labs by 32.3% during the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock valued at $378,000 after acquiring an additional 2,000 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Establishment Labs in the fourth quarter valued at approximately $5,494,000. Finally, Black Swift Group LLC grew its position in Establishment Labs by 98.6% in the fourth quarter. Black Swift Group LLC now owns 14,300 shares of the company's stock worth $659,000 after acquiring an additional 7,100 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on ESTA. Needham & Company LLC upgraded shares of Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 price target on the stock in a report on Wednesday, May 14th. Stephens reissued an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a research report on Thursday, March 6th. Finally, BTIG Research started coverage on shares of Establishment Labs in a research report on Friday, May 16th. They set a "buy" rating and a $62.00 target price on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $55.33.
View Our Latest Stock Analysis on Establishment Labs
Establishment Labs Stock Performance
ESTA stock traded down $1.78 during mid-day trading on Wednesday, reaching $35.88. 327,899 shares of the stock traded hands, compared to its average volume of 471,134. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $58.00. The business has a 50-day moving average of $34.42 and a two-hundred day moving average of $38.10. The firm has a market capitalization of $1.04 billion, a PE ratio of -13.91 and a beta of 0.73.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.13. The business had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm's revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.58) earnings per share. As a group, equities analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.
Establishment Labs Company Profile
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Featured Articles
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
